aTENSION.life GmbH
aTENSION.life GmbH is a company focused on health diagnostics, as indicated by its CEO's investment focus on techbio and diagnostics and its contact email domain 'aldotest'.
Classification
Profile
Funding
2.1 1-line promise · Clinical accuracy - mass-spectrometry measurement of Angiotensin II and Aldosterone eliminates drug-interference that plagues ELISA kits · Speed & convenience - one-shot assay replaces multi-step screening algorithms, delivering results in <24 h
Clinical decision-makers - cardiologists, hypertension specialists, endocrinologists, primary-care physicians who need reliable diagnostics · Diagnostic laboratories - both LC-MS/MS-equipped labs and partner labs that will run the ALDO+PA assay under a service agreement · Health-system purchasers / Payers - hospitals, integrated delivery networks,
Per-test fee - reimbursable CPT/DRG code (once secured) paid by hospitals or insurers · Lab-service subscription - fixed-price annual contracts for kit supply and assay execution · Technology licensing - royalties from third-party labs that adopt the ALDO+ platform under a license
Direct sales force targeting hospital labs and large diagnostic networks · Partner-lab network - agreements with certified labs (e.g., labors.at) that run the test on behalf of clinicians · Digital ordering platform - web portal for test requisition, sample tracking, and result delivery
Laboratories - labors.at and other regional labs that provide the testing infrastructure · Instrument manufacturers - LC-MS/MS vendors (e.g., Thermo Fisher, Sciex) for hardware compatibility and joint marketing · Healthcare systems - pilot programs with hospitals to embed the test into hypertension clinics
R&D & clinical validation - assay optimization, biomarker discovery, and multi-center trials · Regulatory & compliance - CE-IVD dossier updates, audit fees, and future FDA filing costs · Manufacturing - raw reagents, kit assembly, packaging, and cold-chain logistics
Proprietary ALDO+PA assay - mass-spectrometry method, patents, and CE-IVD dossier · Scientific & regulatory team - expertise in hypertension biology, clinical validation, and EU/US regulatory pathways · Manufacturing & supply chain - GMP-compliant kit production facilities
Assay development & validation - ongoing clinical studies to expand indications (e.g., resistant hypertension) · Regulatory compliance - CE-IVD maintenance, preparation for FDA 510(k) submission · Manufacturing & logistics - kit assembly, quality control, and distribution to partner labs
Consultative onboarding - on-site training, assay validation support, and workflow integration assistance · Continuous technical support - 24/7 helpline, remote troubleshooting, and periodic performance audits · Data-driven insights - dashboards that correlate test results with treatment outcomes, fostering a “learning health-system” loop
| Competitor | Core Offering | Strengths | Weaknesses vs. aTENSION |
- Low screening rates for primary aldosteronism – Clinicians cite lack of reliable, easy‑to‑order tests; they are willing to adopt a single, medication‑free assay that fits existing lab workflows.
- Trial‑and‑error antihypertensive therapy – Leads to higher drug costs and adverse events; payers will reimburse diagnostics that demonstrably reduce downstream cardiovascular expenditures.
- Regulatory and reimbursement uncertainty – Hospitals seek CE‑IVD‑certified kits to avoid compliance risk; aTENSION’s certification removes a major barrier.
- Accelerate reimbursement pathways - Initiate parallel FDA 510(k) filing while expanding CE-IVD coverage to secure US payer reimbursement
Rapid DACH rollout - Leverage existing CE-IVD status and partner labs to capture >15 % of the Austrian and German PA testing market within 1 · Reimbursement-driven scaling - Secure national health-system coverage (e.g., Austria’s G-KV, Germany’s G-KV) to create a volume-based revenu · Data-centric ecosystem - Position the analytics dashboard as a “
- Regulatory validation - The ALDO+PA test holds CE-IVD certification, confirming compliance with EU medical-device standards and enabling
No investors recorded yet.